source
- Cavalry Biosciences pursues $75M Series B to test eye and muscle disorder drugsCavalry Biosciences, the first biotech out of incubator and investor Jupiter Bioventures, is working on a $75 million Series B to bring its first two drug candidates into clinical testing, CEO Pres…Endpoints · 1mo ago↗ source
- STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and moreLilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug retatrutideSTAT · 1mo ago↗ source
- #ADA26: Novo Nordisk targets 2030 launch for triple-G obesity shotThe molecules known as triple-Gs — agonists of GLP-1, GIP and glucagon — are drawing attention as data build suggesting they could be the most effective class of obesity drugs. Eli Lilly is leading…